Pulmonx Q1 revenue falls 9% YoY to $20.6M; net loss $13.7M

Pulmonx Corp

2026-Q1 EPS reported -$0.33 revenue$20,586,000

Worldwide revenue $20.6M (-9% YoY, -12% constant currency); U.S. $13.3M (-7%), international $7.3M (-12%).
Ex-China international revenue grew 22% YoY; China sales paused awaiting registration renewal.
Gross margin improved to 78% (vs 73% Q1 2025); total op. expenses $29.0M (-6% YoY).
Adjusted EBITDA loss $8.5M; net loss $13.7M ($0.33 per share) vs $14.4M ($0.36) a year ago.
FY 2026 outlook reaffirmed: revenue $90-92M, gross margin ~75%, opex $113-115M, cash burn ~$23M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Pulmonx Corp reported the first quarter of 2026 ended March 31, 2026 results: revenue $20.6 million, net income Net loss in the first quarter of 2026 was $13.7 million, EPS $0.33 per share. Guidance reaffirmed.

Period: the first quarter of 2026 ended March 31, 2026
Revenue: $20.6 million
Net income: Net loss in the first quarter of 2026 was $13.7 million
EPS: $0.33 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026. Recent Highlights • Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basis • Delivered $13.3 million in U.S. revenue in the

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Pulmonx Corp filing history →

Source: SEC EDGAR

accession 0001127537-26-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.